Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?
Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity. Methods. We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had be...
Gespeichert in:
| Veröffentlicht in: | International Journal of Chronic Diseases 2016-01, Vol.2016 (2016), p.1-7 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 2016 |
| container_start_page | 1 |
| container_title | International Journal of Chronic Diseases |
| container_volume | 2016 |
| creator | Fadhel, Najjar Mohamed Mohamed, Soltani Fadoua, Neffati Sonia, Triki Kawthar, Younes Mounira, Sahtout Ahlem, Bellaleh Nabil, Harzallah Belguith Asma, Sriha Afifa, Koubaa Ilhem, Hellara |
| description | Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity. Methods. We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had been used as a gold standard. Results. Prevalence of MA was 23%, CI 95%: 16.9–29.1. MT validity was 77% for sensitivity, 88% for negative predictive value, and 0.2 for Kappa coefficient (p=0.001). Among subjects having a blood pressure ≥130/80 mmHg, having a CHT/HDL ratio ≥ 3, being a T2D for more than 5 years, and being women, negative predictive values were, respectively, 91%, 89%, 95%, and 91%. The area under the ROC curve was 0.81 in men (p=0.008) and 0.80 when diabetes duration exceeds 5 years (p=0.001). The MA value at 100% Sp for MT was 35 mg/L. Conclusion. The use of MT in primary healthcare for yearly screening for MA in T2D must be accentuated especially when diabetes duration exceeds 5 years or when associated with other cardiovascular risks. |
| doi_str_mv | 10.1155/2016/2910627 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4887651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A515580073</galeid><sourcerecordid>A515580073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3867-60424821189c54985acbea01a4b8c51f9f942aebd7c41a43d553b94c916a4dfb3</originalsourceid><addsrcrecordid>eNqNkt9rFDEQxxdRbKl981kWBBF028zmxyY-KEf9Vaj6YBV8Ctns7G0kl5yb3Zb-9-a4s_bAB8lDMpPP90smM0XxGMgJAOenNQFxWisgom7uFYc1BVbxhqn7mzMXlVASDorjlH4SQoAykLR5WBzUTa0YqPqw-PHVjojBhWXZx7H8jOthjGszDTelC-VbZ1qcMJWf0Hs3zelVeZ4DZ0fjq0tMU_ndeNeVZhWzwcL7ncLZ9OZR8aA3PuHxbj8qvr1_d3n2sbr48uH8bHFRWSpFUwnCaiZrAKksZ0pyY1s0BAxrpeXQq16x2mDbNZblJO04p61iVoEwrOtbelS83vqu53aFncUw5dfp9ehWZrzR0Ti9fxPcoJfxSjMpG8EhGzzfGYzx15yL0iuXbC7YBIxz0tAoISTNeEafbtGl8ahd6GN2tBtcL3juhySkoZk6-QeVV4crZ2PA3uX8nuDZHcGAxk9Din6eXAxpH3y5Be0YUxqxvy0TiN4MhN4MhN4NRMaf3P2aW_hP-zPwYgsMLnTm2v2nHWYGe_OXBsI5MPobmXbEaw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1796683488</pqid></control><display><type>article</type><title>Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Fadhel, Najjar Mohamed ; Mohamed, Soltani ; Fadoua, Neffati ; Sonia, Triki ; Kawthar, Younes ; Mounira, Sahtout ; Ahlem, Bellaleh ; Nabil, Harzallah ; Belguith Asma, Sriha ; Afifa, Koubaa ; Ilhem, Hellara</creator><contributor>Klotsche, Jens</contributor><creatorcontrib>Fadhel, Najjar Mohamed ; Mohamed, Soltani ; Fadoua, Neffati ; Sonia, Triki ; Kawthar, Younes ; Mounira, Sahtout ; Ahlem, Bellaleh ; Nabil, Harzallah ; Belguith Asma, Sriha ; Afifa, Koubaa ; Ilhem, Hellara ; Klotsche, Jens</creatorcontrib><description>Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity. Methods. We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had been used as a gold standard. Results. Prevalence of MA was 23%, CI 95%: 16.9–29.1. MT validity was 77% for sensitivity, 88% for negative predictive value, and 0.2 for Kappa coefficient (p=0.001). Among subjects having a blood pressure ≥130/80 mmHg, having a CHT/HDL ratio ≥ 3, being a T2D for more than 5 years, and being women, negative predictive values were, respectively, 91%, 89%, 95%, and 91%. The area under the ROC curve was 0.81 in men (p=0.008) and 0.80 when diabetes duration exceeds 5 years (p=0.001). The MA value at 100% Sp for MT was 35 mg/L. Conclusion. The use of MT in primary healthcare for yearly screening for MA in T2D must be accentuated especially when diabetes duration exceeds 5 years or when associated with other cardiovascular risks.</description><identifier>ISSN: 2356-6981</identifier><identifier>EISSN: 2314-5749</identifier><identifier>DOI: 10.1155/2016/2910627</identifier><identifier>PMID: 27294192</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Diabetics ; Family medicine ; Kidney diseases ; Medical screening ; Primary health care</subject><ispartof>International Journal of Chronic Diseases, 2016-01, Vol.2016 (2016), p.1-7</ispartof><rights>Copyright © 2016 Koubaa Afifa et al.</rights><rights>COPYRIGHT 2016 John Wiley & Sons, Inc.</rights><rights>Copyright © 2016 Koubaa Afifa et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3867-60424821189c54985acbea01a4b8c51f9f942aebd7c41a43d553b94c916a4dfb3</citedby><cites>FETCH-LOGICAL-c3867-60424821189c54985acbea01a4b8c51f9f942aebd7c41a43d553b94c916a4dfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887651/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887651/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27294192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Klotsche, Jens</contributor><creatorcontrib>Fadhel, Najjar Mohamed</creatorcontrib><creatorcontrib>Mohamed, Soltani</creatorcontrib><creatorcontrib>Fadoua, Neffati</creatorcontrib><creatorcontrib>Sonia, Triki</creatorcontrib><creatorcontrib>Kawthar, Younes</creatorcontrib><creatorcontrib>Mounira, Sahtout</creatorcontrib><creatorcontrib>Ahlem, Bellaleh</creatorcontrib><creatorcontrib>Nabil, Harzallah</creatorcontrib><creatorcontrib>Belguith Asma, Sriha</creatorcontrib><creatorcontrib>Afifa, Koubaa</creatorcontrib><creatorcontrib>Ilhem, Hellara</creatorcontrib><title>Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?</title><title>International Journal of Chronic Diseases</title><addtitle>Int J Chronic Dis</addtitle><description>Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity. Methods. We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had been used as a gold standard. Results. Prevalence of MA was 23%, CI 95%: 16.9–29.1. MT validity was 77% for sensitivity, 88% for negative predictive value, and 0.2 for Kappa coefficient (p=0.001). Among subjects having a blood pressure ≥130/80 mmHg, having a CHT/HDL ratio ≥ 3, being a T2D for more than 5 years, and being women, negative predictive values were, respectively, 91%, 89%, 95%, and 91%. The area under the ROC curve was 0.81 in men (p=0.008) and 0.80 when diabetes duration exceeds 5 years (p=0.001). The MA value at 100% Sp for MT was 35 mg/L. Conclusion. The use of MT in primary healthcare for yearly screening for MA in T2D must be accentuated especially when diabetes duration exceeds 5 years or when associated with other cardiovascular risks.</description><subject>Diabetics</subject><subject>Family medicine</subject><subject>Kidney diseases</subject><subject>Medical screening</subject><subject>Primary health care</subject><issn>2356-6981</issn><issn>2314-5749</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNqNkt9rFDEQxxdRbKl981kWBBF028zmxyY-KEf9Vaj6YBV8Ctns7G0kl5yb3Zb-9-a4s_bAB8lDMpPP90smM0XxGMgJAOenNQFxWisgom7uFYc1BVbxhqn7mzMXlVASDorjlH4SQoAykLR5WBzUTa0YqPqw-PHVjojBhWXZx7H8jOthjGszDTelC-VbZ1qcMJWf0Hs3zelVeZ4DZ0fjq0tMU_ndeNeVZhWzwcL7ncLZ9OZR8aA3PuHxbj8qvr1_d3n2sbr48uH8bHFRWSpFUwnCaiZrAKksZ0pyY1s0BAxrpeXQq16x2mDbNZblJO04p61iVoEwrOtbelS83vqu53aFncUw5dfp9ehWZrzR0Ti9fxPcoJfxSjMpG8EhGzzfGYzx15yL0iuXbC7YBIxz0tAoISTNeEafbtGl8ahd6GN2tBtcL3juhySkoZk6-QeVV4crZ2PA3uX8nuDZHcGAxk9Din6eXAxpH3y5Be0YUxqxvy0TiN4MhN4MhN4NRMaf3P2aW_hP-zPwYgsMLnTm2v2nHWYGe_OXBsI5MPobmXbEaw</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Fadhel, Najjar Mohamed</creator><creator>Mohamed, Soltani</creator><creator>Fadoua, Neffati</creator><creator>Sonia, Triki</creator><creator>Kawthar, Younes</creator><creator>Mounira, Sahtout</creator><creator>Ahlem, Bellaleh</creator><creator>Nabil, Harzallah</creator><creator>Belguith Asma, Sriha</creator><creator>Afifa, Koubaa</creator><creator>Ilhem, Hellara</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?</title><author>Fadhel, Najjar Mohamed ; Mohamed, Soltani ; Fadoua, Neffati ; Sonia, Triki ; Kawthar, Younes ; Mounira, Sahtout ; Ahlem, Bellaleh ; Nabil, Harzallah ; Belguith Asma, Sriha ; Afifa, Koubaa ; Ilhem, Hellara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3867-60424821189c54985acbea01a4b8c51f9f942aebd7c41a43d553b94c916a4dfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Diabetics</topic><topic>Family medicine</topic><topic>Kidney diseases</topic><topic>Medical screening</topic><topic>Primary health care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fadhel, Najjar Mohamed</creatorcontrib><creatorcontrib>Mohamed, Soltani</creatorcontrib><creatorcontrib>Fadoua, Neffati</creatorcontrib><creatorcontrib>Sonia, Triki</creatorcontrib><creatorcontrib>Kawthar, Younes</creatorcontrib><creatorcontrib>Mounira, Sahtout</creatorcontrib><creatorcontrib>Ahlem, Bellaleh</creatorcontrib><creatorcontrib>Nabil, Harzallah</creatorcontrib><creatorcontrib>Belguith Asma, Sriha</creatorcontrib><creatorcontrib>Afifa, Koubaa</creatorcontrib><creatorcontrib>Ilhem, Hellara</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International Journal of Chronic Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fadhel, Najjar Mohamed</au><au>Mohamed, Soltani</au><au>Fadoua, Neffati</au><au>Sonia, Triki</au><au>Kawthar, Younes</au><au>Mounira, Sahtout</au><au>Ahlem, Bellaleh</au><au>Nabil, Harzallah</au><au>Belguith Asma, Sriha</au><au>Afifa, Koubaa</au><au>Ilhem, Hellara</au><au>Klotsche, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?</atitle><jtitle>International Journal of Chronic Diseases</jtitle><addtitle>Int J Chronic Dis</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><issue>2016</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2356-6981</issn><eissn>2314-5749</eissn><abstract>Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity. Methods. We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had been used as a gold standard. Results. Prevalence of MA was 23%, CI 95%: 16.9–29.1. MT validity was 77% for sensitivity, 88% for negative predictive value, and 0.2 for Kappa coefficient (p=0.001). Among subjects having a blood pressure ≥130/80 mmHg, having a CHT/HDL ratio ≥ 3, being a T2D for more than 5 years, and being women, negative predictive values were, respectively, 91%, 89%, 95%, and 91%. The area under the ROC curve was 0.81 in men (p=0.008) and 0.80 when diabetes duration exceeds 5 years (p=0.001). The MA value at 100% Sp for MT was 35 mg/L. Conclusion. The use of MT in primary healthcare for yearly screening for MA in T2D must be accentuated especially when diabetes duration exceeds 5 years or when associated with other cardiovascular risks.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>27294192</pmid><doi>10.1155/2016/2910627</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2356-6981 |
| ispartof | International Journal of Chronic Diseases, 2016-01, Vol.2016 (2016), p.1-7 |
| issn | 2356-6981 2314-5749 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4887651 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | Diabetics Family medicine Kidney diseases Medical screening Primary health care |
| title | Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A35%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20for%20Nephropathy%20in%20Diabetes%20Mellitus:%20Is%20Micral-Test%20Valid%20among%20All%20Diabetics?&rft.jtitle=International%20Journal%20of%20Chronic%20Diseases&rft.au=Fadhel,%20Najjar%20Mohamed&rft.date=2016-01-01&rft.volume=2016&rft.issue=2016&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2356-6981&rft.eissn=2314-5749&rft_id=info:doi/10.1155/2016/2910627&rft_dat=%3Cgale_pubme%3EA515580073%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1796683488&rft_id=info:pmid/27294192&rft_galeid=A515580073&rfr_iscdi=true |